tesamorelin

Known as: GHRH(1-44), N-[(3E)-1-oxo-3-hexenyl]Somatoliberin (human pancreatic islet) 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2016
024620062016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
BACKGROUND AND OBJECTIVES Tesamorelin is a synthetic analogue of growth hormone-releasing factor (GRF), which increases basal and… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2012
2012
BACKGROUND Tesamorelin, a growth hormone-releasing hormone analogue, decreases visceral adipose tissue (VAT) by 15%-20% over 6-12… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
2011
2011
HIV-infected patients on highly active antiretroviral therapy (HAART) develop a complex of body composition changes known… (More)
Is this relevant?
2011
2011
OBJECTIVE To report the effects of tesamorelin, a growth hormone-releasing hormone analogue, on inflammatory and fibrinolytic… (More)
Is this relevant?
2011
2011
Metabolic complications are common in treated HIV patients. Their etiology is multifactorial and the development of increased… (More)
Is this relevant?
2010
2010
CONTEXT HIV patients treated with antiretroviral therapy (ART) often develop increased visceral adipose tissue (VAT). OBJECTIVE… (More)
Is this relevant?
2010
2010
BACKGROUND HIV-infected patients receiving antiretroviral therapy often demonstrate excess visceral fat. A growth hormone… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2008
2008
OBJECTIVE Treatment of HIV patients with daily tesamorelin, a growth hormone-releasing factor analogue, for 26 weeks resulted in… (More)
Is this relevant?
2007
2007
BACKGROUND Visceral adipose tissue accumulates during antiretroviral therapy in many patients who are infected with the human… (More)
Is this relevant?
Review
2006
Review
2006
Theratechnologies, under license from Valeant, is developing tesamorelin as a potential vaccine adjuvant and for the potential… (More)
Is this relevant?